Psychedelic Medicine News Articles
Below are key excerpts of inspiring news articles on psychedelic medicine from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.
The brew is so potent that practitioners report not only powerful hallucinations, but near-death experiences, contact with higher-dimensional beings, and life-transforming voyages through alternative realities. Often before throwing up, or having trouble at the other end. Now, scientists have gleaned deep insights of their own by monitoring the brain on DMT, or dimethyltryptamine, the psychedelic compound found in Psychotria viridis, the flowering shrub that is mashed up and boiled in the Amazonian drink, ayahuasca. The recordings reveal a profound impact across the brain, particularly in areas that are highly evolved in humans and instrumental in planning, language, memory, complex decision-making and imagination. The regions from which we conjure reality become hyperconnected, with communication more chaotic, fluid and flexible. “It is incredibly potent,” said Robin Carhart-Harris, a professor of neurology and psychiatry. “People describe leaving this world and breaking through into another that is incredibly immersive and richly complex, sometimes being populated by other beings that they feel might hold special power over them, like gods.” He added: “DMT breaks down the basic networks of the brain, causing them to become less distinct from each other. The major rhythms of the brain – that serve a largely inhibitory, constraining function – break down, and in concert, brain activity becomes more entropic or information-rich.”
Note: Read more about the healing potentials of mind-altering drugs. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Against all odds, Jim Harris was walking. There he was, at a music festival, getting around with the assistance of a walker, eight months out from a spinal-cord injury that left him paralyzed from the chest down. In November 2014, a snowkiting accident in Chile changed how the mountaineering instructor turned adventure photographer moved through the world. His days ... were now filled with rehabilitation exercises. A friend and former physical therapist invited him to the High Sierra Music Festival. "The disability made me feel like an outsider," he says. Then someone offered him magic mushrooms, which are packed with the psychoactive compound psilocybin. He commandeered an acquaintance's padded knee scooter so he could rest one leg at a time and still sway to the music. In the middle of a switch, he discovered that he could pick up his right foot and pull it back toward his butt. He tapped his right hamstring with a finger and the muscle contracted - a muscle that had been completely unresponsive since his injury, even in the low-gravity environment of a pool, despite eight months of physical therapy. With wonder and some degree of hesitation, he showed his physical-therapist friend. They marveled together at what had been impossible for Harris earlier that day. The next morning, Harris woke up afraid he'd imagined the whole thing, or that he'd lost his newfound ability while he slept, but his hamstring was still firing. The neuromuscular connection that had formed the night before wasn't going anywhere.
Note: Read more about the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Psychedelic therapy is the use of psychedelic substances, often alongside traditional talk therapy (psychotherapy), as a treatment for mental health issues such as anxiety, depression, suicidality and PTSD. Michael Mithoefer, M.D. ... at the Multidisciplinary Association for Psychedelic Studies (MAPS), likens psychedelic therapy to applying a cast to a broken bone. “[Psychedelic]-assisted therapy engages the mind’s innate power to heal itself—the participants’ ‘inner healing intelligence,’” claims Dr. Mithoefer, going on to explain that “the source of the healing process is the person themselves—the psychedelic and therapists are catalysts.” In the U.S., psychedelics continue to undergo medical trials, with some being granted a “breakthrough therapy” designation by the FDA, indicating that preliminary clinical evidence has shown the drug can demonstrate substantial improvement over currently available therapy. COMPASS Pathways, a mental health treatment company, received the designation for its psilocybin therapy for treatment-resistant depression in 2018. In 2019, Usona Institute ... received the designation to continue its testing of psilocybin as a treatment for major depressive disorder. Psilocybin-assisted therapy is also being tested as a treatment for various addictions ... as well as certain conditions such as anxiety, depression, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), cluster headaches, migraines and chronic pain.
Note: Read more about the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Dead Dog on the Left isnt just a documentary about the use of ecstasy in treating PTSD, its a story of the lengths one former marine will go to for friendship. [Tyler] McCourry and [Nigel] Flanigan are the subjects of [the] mini-documentary taken from a forthcoming feature film, MDMA the Movie, which explores the history of the so-called party drug more popularly known as ecstasy, its use in therapy, and harm reduction. Both films are directed by Emanuel Sferios. His protagonists may have survived the Iraq war, but only barely. Suicidal thoughts have stalked them both. In May 2012 McCourry did his first [MDMA-assisted psychotherapy] session ... lying in bed, flanked by two therapists. At the beginning of the session he was given a 75mg dose of MDMA. During those eight hours youre addressing the most challenging situations in your life, he says. It feels very exhausting, like it was some of the most work youve ever done in one day. McCourry calls those trials, now completed, a transformation of the psyche. MDMA-assisted psychotherapy has breakthrough therapy designation by the FDA. Since the MDMA therapy Im able to recognise when something comes up that I need to talk about, [McCourry] says. McCourry hopes that the therapy will be adopted by the Veterans Administration and Department of Defense. If you can cure PTSD after three sessions of MDMA therapy then you dont have to provide a veteran with medications for the rest of their life and talk therapy once a month.
Note: A touching 26-documentary on this case is available at the above link. Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream scientific credibility.
For most, psychedelic drugs conjure up images of the 1960's, hippies tripping out on LSD or magic mushrooms. But ... these powerful, mind-altering substances are now being studied seriously by scientists inside some of the country's foremost medical research centers. They're being used to treat depression, anxiety and addiction. The early results are impressive, as are the experiences of the studies' volunteers who go on a six-hour, sometimes terrifying, but often life-changing psychedelic journey. For nearly two decades now, [scientist Roland Griffiths] and his colleague Matthew Johnson have been giving what they call "heroic doses" of psilocybin to more than 350 volunteers, many struggling with addiction, depression and anxiety. Carine McLaughlin was a smoker for 46 years and said she tried everything to quit before being given psilocybin at Johns Hopkins last year. That was more than a year ago; she says she hasn't smoked since. The study she took part in is still ongoing, but in an earlier, small study of just 15 long-term smokers, 80% had quit six months after taking psilocybin. That's double the rate of any over-the-counter smoking cessation product. Jon Kostakopoulos was drinking a staggering 20 cocktails a night ... when he decided to enroll in another psilocybin trial at New York University. During one psilocybin session, he was flooded with powerful feelings and images from his past. He took psilocybin in 2016. He says he hasn't had a drink since.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
The US Food and Drug Administration approved Janssen Pharmaceuticals Inc.'s esketamine on Tuesday for treatment-resistant depression; the drug is the chemical cousin of ketamine, the powerful anesthetic that has been used illegally as the club drug Special K. It will be sold as Spravato. It's for patients who have tried at least two other medications without success, and it should be taken with an oral antidepressant. "There has been a longstanding need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition," Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products at the FDA's Center for Drug Evaluation and Research, said. Spravato is a nasal spray administered by an approved health care provider in a doctor's office or a medical clinic. It may also be self-administered but only under the supervision of a care provider and cannot be taken home. Depending on the severity of the patient's depression, it is given either once a week or once every other week. The drug is rapidly acting, so it starts working faster than other antidepressants, according to Janssen. It works by restoring brain cells in patients with treatment-resistant depression. Currently available treatments for major depression are ineffective in 30% to 40% of patients. The drug was designated as a breakthrough therapy in 2013, a status intended to "expedite the development and review of drugs for serious or life-threatening conditions," the FDA said at the time.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
Aaron Rodgers and Kenny Stills are among the few who have spoken publicly about their use of psychedelics for mental health purposes. But a future where the treatment is more widespread across sports may not be so far away. “Some people still ... don’t recognize these as legitimate, life-saving medical medicines,” [NBA agent Daniel] Poneman says. “There are athletes that I know who have had life-changing experiences with these medicines, but only a few of them are brave enough to speak out for fear of being stigmatized.” There’s still stigma around taking medication of any kind for mental illness, but it’s slowly lessening. Aaron Rodgers said on a recent podcast that he has taken psychedelics to improve his mental health. The Packers’ quarterback said he does not identify as having a mental illness like depression or anxiety, but that his most recent psychedelic experience—with ayahuasca, in March 2020, in Peru—has helped increase his “self-love.” Before Rodgers spoke out, NFL free-agent wide receiver Kenny Stills was thought to be the only active professional athlete vocal about his psychedelic use. Stills, who last season played for the Saints, says his case of depression in 2016 felt like a “permanent cloud.” Last year he went to a clinic run by Field Trip Health, a for-profit that provides people with ketamine-assisted psychotherapy—meaning they have to take the medication under supervision of a licensed therapist and debrief with them afterward.
Note: Read more about the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
In May, a long-awaited randomized, double-blind, placebo-controlled, Phase 3 clinical trial testing MDMA-assisted therapy for the treatment of PTSD was published in Nature Medicine. The trial was conducted by MAPS Public Benefit Corporation, a for-profit subsidiary launched by the registered non-profit in 2014, with the goal of conducting the necessary research to make MDMA a legally available medicine. “We are a for-profit, but we’re wholly owned. We only have one shareholder, and it’s a non-profit,” says CEO Amy Emerson. While a non-profit is tax exempt and operates for charity, the PBC, like a traditional corporation, pays taxes, operates for profit, and has shareholders and stocks. The results of the Phase 3 clinical trial conducted by MAPS PBC revealed that after receiving a combination of talk therapy and MDMA, 67 percent of participants who received the drug no longer met the diagnostic criteria for PTSD, compared to 32 percent of participants who received the placebo. The trial was recently acknowledged as a “big win for the field” in Science Magazine’s annual Breakthrough of the Year awards. “In our three-session model, there’s no follow-up medication needed,” [MAPS CMO Dr. Corine de Boer] says. After pooling the data of six Phase 2 trials together, de Boer’s team found that 57 percent of participants no longer met the criteria for PTSD. At a one-year follow-up during which no MDMA was administered, that number increased to 67 percent.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.
There is clearly a psychedelic renaissance underway. These agents are now debated at medical conferences smirk-free, and my investment-obsessed friends predict a financial “‘shroom-boom”. During the 2020 US election ... Measure 109 asked voters in Oregon whether magic mushrooms should be allowed for medical purposes, and Initiative 81 asked Washingtonians about decriminalizing psychedelic plants and fungi. Research is also underway in institutions from Johns Hopkins to Imperial College London. Recently, Health Canada quietly ... allowed four terminally ill patients to take psilocybin under medical supervision. I have also been asked by several patients, at end-of-life, to prescribe a gram of mushrooms or a tablet of lysergic acid diethylamine (which my pharmacy cannot furnish), rather than a “bucket of fentanyl” (which the pharmacy readily can). The Default Mode Network (DMN) ... refers to interconnected brain regions that help us believe we are a distinct self, separate from others and the natural world. This drives self-reliance, but can make us feel isolated. Moreover, as it “matures,” we respond in more habitual, predictable, rigid ways. The theory is that DMN overactivity leads to excessive introspection, hypercriticism, obsession, depression, and anxiety. Psychedelics might decrease the tyranny of the DMN, thereby allowing unfamiliar parts of the brain to go on a play-date. We should not throw out the scientific method, but psychedelics could increase the colors in our crayon set.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind-altering drugs from reliable major media sources.
At 74, the venture capitalist George Sarlo might not have seemed an obvious candidate for an ayahuasca experience. Mr. Sarlos close friend, a doctor, told him about ayahuasca, a psychedelic brew made from the Banisteriopsis caapi vine, native to the Amazon. Used for centuries in sacred healing traditions throughout Central and South America, ayahuasca is now gaining popularity around the world. [It] is mostly illegal in the United States. Notably, ayahuascas increasing popularity knows no age limits: many of those now showing interest are squarely in Mr. Sarlos own demographic. Mr. Sarlo himself was initially skeptical. Taking ayahuasca would entail a potentially distressing night of hallucinations, and excretions of all kind, especially vomiting. But he still decided to head to Yelapa, a small village in Mexico, and swallow down the bitter brew. Mr. Sarlo said that afterward, something shifted. It changed my life completely. He realized that his life had been absolutely full of miracles, he said. As Michael Pollan put it, psychedelics might be wasted on the young. Mr. Pollan, the author of the recent best seller How To Change Your Mind, a history of psychedelics and a chronicle of his own experiences trying them, said ... he was surprised by the number of people he encountered when writing his book in their 70s and 80s expressing interest in trying psychedelics. Though perhaps he shouldnt have been: as he himself has written, one of the reasons to come to psychedelics later in life is to tangle with ones own mortality.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that Cartography of the Mind: A Curated NFT Sale raised $1,569,960. Proceeds of the auction, presented by Christies in collaboration with Ryan Zurrer, founder of Dialectic and Vine Ventures, will benefit MAPS. Throughout the week, the physical exhibition at Christie's new gallery on 6th Avenue drew impressive crowds of enthusiastic visitors. With competitive bidding, the sale realized over $1.5 million. It was 100% sold, and 130% sold hammer over low estimate. Beeple, David Choe, Sarah Meyohas, Refik Anadol, Mad Dog Jones, IX Shells, and more donated art to support MAPS. The research, education, and advocacy organization ... remains the leading body at the vanguard of research into potentially life-saving psychedelic-assisted therapies. Psychedelic Healing is an artistic interpretation of the MAPS logo by renowned artist Alex Grey to celebrate MAPS' 35th anniversary in 2021. It was purchased by Ryan Zurrer and donated back to MAPS for additional fundraising. Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization developing medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world funded primarily by philanthropic donors and grantors who have given more than $130 million for research and education.
Note: Read more about the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Growing evidence for the safety and efficacy of psychedelics could lead to better treatments for anxiety, depression, pain, and other often intractable conditions. Jerry Rosenbaum was intrigued when he first heard about the effect that psilocybin—the hallucinogenic compound found in certain species of mushrooms—was purported to have on the brain’s “resting state,” what neuroscientists call the default mode network. The default mode network encompasses any neural function that has some bearing on our autobiographical tendencies. When people take psilocybin at low doses, the default mode network becomes less active. That is, the drug appears to tame self-reflection and all but ruin rumination, that obsessive mental state characterized by excessive, repetitive thoughts. Rumination is a hallmark cognitive symptom of depression. Neuroscientists are observing that, when taken in a controlled setting, these substances are beneficial to the brain, especially for people who have certain psychiatric disorders. Landmark studies in 2014 and 2016 showed that LSD and psilocybin alleviated existential anxiety in patients with life-threatening illnesses for up to a year after beginning the treatment. Other studies have shown that ketamine may strengthen neurons against the damage from chronic stress by preventing synapses from being flooded with glutamate, an amino acid that, in excess, withers dendrites. And researchers continue to investigate whether psychedelics are useful as anti-inflammatory agents.
Note: Read more about the healing potentials of psychedelic medicine. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Evan, a middle-class Black man, doesn’t come across as a psychedelic enthusiast. He’s a 23-year-old quantitative economics graduate student who takes pride in steaming his sweater vests to maintain a studious appearance. In 2015, Evan’s father was arrested for misdemeanor drug possession. A teenager at the time, he swore off drugs forever. But six years later, magic mushrooms have become Evan’s remedy to cope with racial trauma. Like most Americans, Evan followed the widespread media coverage of George Floyd and Breonna Taylor’s deaths in 2020. And like many Black Americans, he experienced traumatic-stress symptoms triggered by the constant exposure to cases of police brutality and racial discrimination. Debilitating panic attacks incapacitated him multiple times a day; insomnia drained his ... energy. After unsuccessfully trying three different anti-anxiety medications, he finally stumbled upon a study on psychedelics for racial trauma. He wondered: could psychedelic therapy be the solution? Psilocybin, the active compound in magic mushrooms, has been found to mitigate acute anxiety among patients with life-threatening cancer. A state-sponsored study in Texas is investigating psychedelics as a treatment for post-traumatic stress disorder in veterans. But one lesser-known benefit has been documented by researchers at the University of Ottawa: psychedelics may alleviate symptoms of race-based traumatic stress.
Note: Read more about the healing potentials of mind-altering drugs. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Berra Yazar-Klosinski [is the] chief scientific officer at the Multidisciplinary Association for Psychedelic Studies (MAPS). I ... committed to working with her on the phase 3 program that would assess the efficacy and safety of MDMA—known recreationally as Molly or Ecstasy—for severe PTSD, or post-traumatic stress disorder. Although more than half a dozen phase 2 studies have demonstrated the effectiveness and safety of MDMA for PTSD, early trials often fail to accurately predict the outcome of the larger, multisite phase 3 trials that follow. In the case of MDMA, we have been lucky. At 15 study sites across three countries, working with more than 70 different therapists and with study participants with childhood trauma, depression and a treatment-resistant subtype of PTSD, we have obtained incredibly promising results. Phase 3 study participants receiving MDMA-assisted therapy showed a greater reduction in PTSD symptoms and functional impairment than participants receiving placebo plus therapy. In addition, their symptoms of depression plummeted. By the end of the study more than 67 percent of the participants in the MDMA group no longer met criteria for PTSD. An additional 21 percent had a clinically meaningful response—in other words, a lessening of anxiety, depression, vigilant mental states, and emotional flatness. MDMA-assisted therapy did not increase measures of suicidal thinking or behavior. MDMA also did not demonstrate any measurable misuse potential.
Note: Read more about the healing potentials of mind-altering drugs. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Fungi have been around for billions of years, setting the stage for humanity by supporting, carrying and converting life. But for complex political reasons, these organisms are still shrouded in mystery. One man, however, is determined to lift the veil on the magical world of mushrooms. Enter Stamets, a bespectacled author and researcher whose mission to decode nature’s hidden language and explore “altered states of consciousness" is chronicled in the documentary “Fantastic Fungi,” which was recently made available to stream on Netflix. While the film aims to destigmatize hallucinogenic mushrooms, it also demonstrates why we should legitimize the studies of all mushrooms. Contemporary experts in neurology, psychiatry and biology in the film show that fungal genomes can solve a host of mental, physical and environmental problems. From healing bacterial infections to cleaning petroleum spills, fungi possess unique, almost godlike properties that are otherwise unseen in nature. For instance, lion’s mane, an edible white mushroom that tastes like lobster, stimulates nerves in order to grow, suggesting that it could potentially cure degenerative diseases like Alzheimer’s. Ultimately, when Stamets discusses altered states of consciousness, it’s ... about accepting a different state of being. For some people — especially those who live in pain — the film posits that mushrooms can be the answer they’ve been looking for.
Note: Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
In the past two years, a new drug policy reform movement called Decriminalize Nature has persuaded local governments in a half dozen municipalities, including Washington, D.C., to decriminalize “plant medicines” such as psilocybin, ayahuasca, iboga and the cactuses that produce mescaline. Last month, the California State Senate passed a bill that would make legal the personal possession, use and “social sharing” of psychedelics, including LSD and MDMA, a.k.a. Ecstasy or Molly. Political opposition to all these measures has been notably thin. Neither party, it seems, has the stomach for persisting in a war that has achieved so little while doing so much damage, especially to communities of color and our civil liberties. But while we can now begin to glimpse an end to the drug war, it is much harder to envision what the drug peace will look like. How will we fold these powerful substances into our society and our lives so as to minimize their risks and use them most constructively? In the case of psychedelics, decriminalizing these powerful compounds is only the first step in a process of figuring out how best to safely weave their use into our society. The main model we have for resocializing a formerly illicit drug is the legalization of cannabis, now the new normal in 18 states. The use of psychedelics by Indigenous peoples ... suggests a model we would do well to keep in mind as we figure out how best to handle these substances.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind altering drugs from reliable major media sources.
In the summer of 1981, when he was 13, Grant crashed a trail motorbike. Grant hadn’t given this childhood memory much thought in the intervening years, but one hot August day ... he suddenly understood it as a clue to his dangerously unhealthy relationship with alcohol. The day before, a team of specialists at the Royal Devon and Exeter hospital had given him an intravenous infusion of ketamine, a dissociative hallucinogen, in common use as an anaesthetic since the 1970s, and more recently one of a group of psychedelic drugs being hailed as a silver bullet in the fight to save our ailing mental health. To date, more than 100 patients with conditions as diverse as depression, PTSD and addiction have been treated in research settings across the UK, using a radical new intervention that combines psychedelic drugs with talking therapy. What was once a fringe research interest has become the foundation of a new kind of healthcare, one that, for the first time in modern psychiatric history, purports to not only treat but actually cure mental ill health. Under its influence, Grant had an out-of-body experience he struggles to put into words. “It was like I was sinking deeper and deeper into myself,” he says. “Then I became white… and I left my body. I was up on the ceiling, looking at myself, but I was just this white entity. I felt very serene and humbled; I finally understood my place in the universe, just a white speck of light, I wasn’t the centre of everything and that was fine.”
Note: For more along these lines, see concise summaries of deeply revealing news articles on the healing potentials of mind altering drugs from reliable major media sources.
Massachusetts General Hospital wouldn’t seem like a natural fit for a center devoted to mind-altering drugs. But this week, MGH launched the Center for the Neuroscience of Psychedelics to study the potential of psilocybin and other psychoactive drugs to treat conditions such as depression, addiction, trauma, and more. The new center at MGH signifies that the field of psychedelic therapy has arrived. Inspiration came from the search for ways to ease the misery of patients whose mental illness is resistant to traditional treatments. Psychedelics are known to facilitate “plasticity” in the brain, increasing its capacity for change, and [director Jerrold] Rosenbaum said his team wanted to understand how these agents “move the brain to change in a way that can address many of the most anguishing forms of human suffering.” The MGH center combines the disciplines of psychiatry, brain imaging, genomic medicine, and chemical biology. Some of the initial work involving patients will use psilocybin and be directed at rumination — the stuck, repetitive thought patterns that underlie several conditions, from addiction to obsessive-compulsive disorder. The future of the center’s research is boundless, since psychedelics’ role in neuroplasticity and neuritogenesis — the ability to build new synapses — may be useful in palliative care with terminally ill patients as well as in combatting neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
Note: This article is also available on this webpage. For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
While I was in anesthesia residency at the University of Southern California Hospital's Department of Anesthesiology from 2006 to 2009, I learned how to put people under for surgery using an anesthetic called ketamine. Afterwards, as I began work as an anesthesiologist at a hospital, I began hearing interesting things about the anesthetic. Researchers had begun testing it as a treatment for mental health conditions like anxiety, depression, and PTSD — and with encouraging results. It also has psychedelic properties, so people can gain insight into their lives and even have mystical experiences on it. One study found that it reduced symptoms of depression and anxiety in patients with severe depression, both immediately after it was administered and as well as a month down the line. Another found that it even provided relief from chronic pain that lasted for up to two weeks after treatment. In 2014, inspired by findings like these and conversations with psychiatrists who were beginning to incorporate ketamine into their practices, I founded the Ketamine Healing Clinic of Los Angeles. Over time, I've seen people undergo big changes in their lives because of their work with ketamine, including a few who left abusive relationships, grew their businesses, or pursued totally new ventures. Overall ... people typically come out of their infusions with a newfound will to live and increased clarity about their future. Some patients who came in with suicidal thoughts no longer have them at all.
Note: Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Older Americans suffer disproportionately from chronic pain and its attendant ailments, anxiety, depression and insomnia. In the search for relief, they consume more pharmaceutical drugs than perhaps any comparable cohort on this planet. Psychedelic therapies to treat mental health conditions offer a radical departure from current pharmaceutical models. The psychedelic therapy modalities currently under investigation combine a limited number of treatment sessions with a psychedelic substance, sandwiched between intensive pre- and post-treatment therapy sessions. The ideal, and realistic, outcome from this course of treatment is not mere symptom control, but durable remission. Indeed, these studies are finding that, in clinically significant numbers, recipients of a single course of psychedelic therapy report the experience to be life-changing, and enduring over time. The positive preliminary outcomes of clinical studies by MAPS using MDMA to treat PTSD, and Compass Pathways for psilocybin therapy for treatment-resistant depression, have convinced the FDA to grant them Breakthrough Therapy Designation. In the 1960s researchers were interested in seeing if psychedelic drug treatment could alleviate existential distress in terminal cancer patients. This line of research was picked up 35 years later by Dr. Charles Grob, whose 2011 pilot study of psilocybin treatment for terminal cancer patients found significant enduring reductions in anxiety and improvement in mood at a six-month follow up.
Note: Read more on the healing potentials of mind-altering drugs. Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
